Could IDT manufacture biosimilar Tocilizumab?

This is just a Monday hypothesis, following the coverage of the upcoming shortage of Actemra (Tocilizumab) on ABC News last night. The Government will need a supply of this drug as an immunosuppressant for COVID 19 patients. Actemra is Evergreen and the patent has expired, but there is a biosimilar (ie: generic) form that could be manufactured .... and maybe IDT have the capability to produce this? Would underpin the Government's strategy to produce drugs onshore. The Government has known about the shortage for several months .... and could produce enough for Australia and even elsewhere? A good news story. I may be wrong!